MavriX Bio, LLC
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome (NCT07181837) | MavriX Bio, LLC | 2025-10-29 |
Track MavriX Bio, LLC automatically
Every clearance here is in the API, with alerts when new ones post.